Biogen Inc. stock gains on China approval for at-home Alzheimer’s treatment

Published on 09/16/2026 at 13:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Biogen Inc. stock closed at USD 216.17 on Nasdaq on September 15, 2026, leaving it about 4.4% below its 52-week high of USD 225.80. The China NMPA’s approval of at-home weekly LEQEMBI dosing adds a new growth lever for Biogen’s Alzheimer’s business.

Fotorealistisches Biotech-Labor in Cambridge MA mit Forscherin am Mikroskop und Blick auf den Charles River — Biogen Inc. Neurowissenschaftslabor in Cambridge MA zeigt Forscherin bei Gehirngewebeanalyse unter Mikroskop ISIN US09062X1037, Illustration mit AI erstellt.

Biogen Inc. stock (ISIN US09062X1037) closed at USD 216.17 on Nasdaq on September 15, 2026, down 0.55% from the prior session and sitting roughly 4.4% below its 52-week high of USD 225.80 as investors digested a major regulatory win in Alzheimer’s treatment.

China clears at-home LEQEMBI dosing

According to Simply Wall St on September 16, 2026, Biogen and its partner Eisai have received approval from China’s National Medical Products Administration for a self-administered subcutaneous formulation of LEQEMBI for early Alzheimer’s disease.

The new LEQEMBI option allows once-weekly at-home subcutaneous dosing via an autoinjector instead of clinic-based infusions, targeting patients with early-stage Alzheimer’s who qualify under the product’s label, as highlighted by Simply Wall St.

Simply Wall St notes that China is only the second country worldwide to clear this at-home subcutaneous version of LEQEMBI, underscoring Biogen’s ambition to expand Alzheimer’s treatment access beyond infusion centers.

Stock valuation and recent fundamentals

In its analysis dated September 16, 2026, Simply Wall St points to an estimated fair value of USD 236 per Biogen share, implying upside of about 9.2% from the September 15, 2026 closing price of USD 216.17 if its valuation assumptions play out.

The same analysis from Simply Wall St references Biogen’s recent fundamentals, framing the China LEQEMBI approval against its broader earnings profile and flagging two warning signs that investors should weigh alongside the new Alzheimer’s growth option.

For context on market performance, Biogen’s 52-week range extends from USD 135.39 at the low to USD 225.80 at the high, according to Nasdaq data reported by CNBC, placing the latest close closer to the upper end of that band.

Price levels and trading context

Per data cited by MarketBeat, Biogen shares closed the regular Nasdaq session on September 15, 2026 at USD 216.17, with an after-hours indication of USD 215.00 later that day.

According to the same Nasdaq quote overview from CNBC, Biogen’s September 15, 2026 session saw a trading volume of 708,173 shares on Nasdaq, compared with an after-hours volume of 47,653 shares.

The same data from CNBC show that at USD 216.17, Biogen’s stock is trading roughly 59.6% above its 52-week low of USD 135.39, a range that illustrates how Alzheimer’s-related developments and broader biotech sentiment have lifted the share price over the past year.

Closing price and investor view

Biogen Inc. stock last closed at USD 216.17 on Nasdaq on September 15, 2026, down 1.19 dollars or 0.55% from the prior close, with the shares positioned in the upper segment of their 52-week band between USD 135.39 and USD 225.80.